Etid klinik pou Limfom nan Utah
13 etid pou Limfom ap chèche patisipan nan sit nan Utah.
Vil nan Utah
Tèks ofisyèl etid la (Anglè)
A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
- Huntsman Cancer Institute, Salt Lake City
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07013435A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- University of Utah, Salt Lake City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07221500CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Primary Children's Hospital, Salt Lake City
Ap rekriteFaz 1/2
12 Months – 21 Years · Tout sèks · Mizajou Sep 11, 2026 · NCT04870944Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT05826535A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
- START Mountain Region, West Valley City
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT06678659A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Intermountain Healthcare, Salt Lake City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT07188558Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jun 1, 2026 · NCT05663502Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
- START Mountain Region, West Valley City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou May 4, 2026 · NCT06132503Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
- START Mountain Region, West Valley City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 24, 2026 · NCT06801002CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT03328078A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 20, 2026 · NCT04830137Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
- Huntsman Cancer Institute at University of Utah, Salt Lake City
Ap rekrite
Laj 21 ak plis · Tout sèks · Mizajou Feb 5, 2026 · NCT07390071A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- University of Utah, Salt Lake City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 14, 2025 · NCT05643742Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.